Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Executive Officer

Chief Operating Officer & GC

Chief Financial Officer

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treat...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-10-20	Premium	acquired	Premium	Premium	Premium	-
2023-10-20	Premium	acquired	Premium	Premium	Premium	-
2023-10-11	Premium	acquired	Premium	Premium	Premium	-
2023-10-11	Premium	acquired	Premium	Premium	Premium	-
2023-09-22	Premium	bought	Premium	Premium	Premium	-
2023-09-22	Premium	bought	Premium	Premium	Premium	-
2023-09-21	Premium	bought	Premium	Premium	Premium	-
2023-09-21	Premium	bought	Premium	Premium	Premium	-
2023-09-20	Premium	bought	Premium	Premium	Premium	-
2023-09-20	Premium	bought	Premium	Premium	Premium	-
2023-02-28	Premium	bought	Premium	Premium	Premium	-
2022-07-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2021-07-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2021-07-02	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer & GC
2021-05-25	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-02-23	Premium	sold	Premium	Premium	Premium	-
2020-07-23	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2020-07-02	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer & GC
2020-07-02	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2019-12-19	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2019-12-19	Premium	bought	Premium	Premium	Premium	-
2019-12-19	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2019-12-19	Premium	bought	Premium	Premium	Premium	-
2019-09-27	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2019-09-06	Premium	bought	Premium	Premium	Premium	-

MEIP - MEI Pharma Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for MEIP